As per the current market research conducted by the CMI Team, the US Regenerative Medicine Market size is expected to record a CAGR of 9.6% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 213.1 Million. By 2032, the valuation is anticipated to reach USD 530.2 Million.
U.S. Regenerative Medicine: Growth Factors and Dynamics
The increasing awareness and preference for the usage of stem cells, tissue engineering, and gene therapies by patients and their families is one of the key factors for the market’s positive growth in the North American region.
Recent research reports indicate that the rising cases of chronic diseases in the U.S. population are another factor for the expansion of the market. According to medical research, at least 40,000 infants born in the U.S. each year are expected to be affected by congenital heart defects. About 25% of 2.4 (per 1,000 live births) require treatment in the first year of life.
Similarly, the rising cases of organ failure amongst the population have led to the demand for organ transplants. Regenerative medicines are widely used in transplant procedures as they aid in the restoration of damaged tissues or entire organs.
According to research by the Centers for Disease Control and Prevention (CDC), at least 26.9 million people in the U.S. are diagnosed with diabetes. They account for approximately 10.5% of the total population of the country. Pharmaceutical companies are developing solutions for diabetes patients who need insulin.
The U.S. population also has disposable income and the government healthcare schemes put regenerative medicines at the core. All these factors foster the expansion of the regenerative medicine market.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 244.88 Million |
| Projected Market Size in 2032 | USD 174.72 Billion |
| Market Size in 2022 | USD 11.13 Billion |
| CAGR Growth Rate | 22.8% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type, Application and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Country Scope | US |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
U.S. Regenerative Medicine Market: COVID-19 Analysis
In the first two waves of the Novel coronavirus, the world and consequently, all industries suffered setbacks. Eventually, everybody learned to live with the virus–Â of course with the help of vaccines, drugs, and immunity boosters.
However, learning to live with the virus was not easy. In the pharma sector, the manufacturers, developers, and healthcare providers had to rejig the way they worked. The move to the digital world was inevitable. The pharmaceutical industry also had to work around the shortages of supplies and had the pause button pressed for clinical trials that affected deliveries.
On the flip side, regenerative medicine and its cell tissue therapeutics became the game changer as one of the possible treatments for those affected by COVID-19. Regenerative medicine offers cell-tissue therapeutics and related products, such as natural killer (NK) cell therapy, Chimeric antigen receptor, stem cell therapy, exosomes, (CAR) T cell therapy, and tissue products. Amongst all these, the mesenchymal stem cells (MSCs) can reduce inflammatory symptoms and protect against cytokine storm, which is one of the critical factors that contribute to the progression of COVID-19 infection.
Interestingly, the NK cells can exert cytotoxic effects on infected cells and induce interferon production, thus becoming a possible candidate to be a part of COVID-19 cell therapy. In addition, exosomes are one of the significant products of cells that offer therapeutic effects through the induction of immune responses. It also helps in neutralizing antibody titers. Although there is no specific cure, as yet, for COVID-19, the options available in regenerative medicine are promising.
List of the prominent players in the U.S Regenerative Medicine Market:
- Organogenesis Holding Inc
- Abbvie Inc (Allergan Plc)
- Intellia Therapeutics
- Bristol Myers Squibb
- Stryker Corporation
- Osiris Therapeutics
- Integra LifeSciences
- Cook Medical
- Others
The U.S Regenerative Medicine Market is segmented as follows:
By Type:
- Cell therapy
- Dermatology
By Application
- Musculoskeletal segment
On the basis of US Geography
- Northeast Region
- Southeast Region
- Midwest Region
- West Coast Region
- Southwest Region
- Mountain States